The lipid-lowering drug fenofibrate as a PPARα agonist induces metabolic reprogramming in oral cancer, changing the protein expression of hexokinase II (HK II), pyruvate kinase, pyruvate dehydrogenase, and voltage-dependent anion channel, thus delaying tumor development (Jan et al., 2016). The gene discussed is PPARA; the disease is neoplasm.